Overview

Carfilzomib/Cyclophosphamide/Dexamethasone With Maintenance Carfilzomib in Multiple Myeloma

Status:
Active, not recruiting
Trial end date:
2029-11-01
Target enrollment:
Participant gender:
Summary
The Cardamon trial is a phase 2 trial using the standard chemotherapy drugs cyclophosphamide and dexamethasone in combination with a new drug called Carfilzomib in patients with multiple myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
University College, London
Collaborators:
Amgen
Onyx Pharmaceuticals
Treatments:
BB 1101
Cyclophosphamide
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate